Literature DB >> 31723466

Psoriasis in Patients With Active Lung Cancer: Is Apremilast a Safe Option?

Zoe Apalla1, Eftychios Psarakis1, Aimilios Lallas2, Alexia Koukouthaki1, Athanassios Fassas3, Maria Smaragdi1.   

Abstract

Entities:  

Keywords:  adenocarcinoma; apremilast; phosphodiesterase inhibitor; psoriasis; treatment

Year:  2019        PMID： 31723466      PMCID： PMC6830556          DOI： 10.5826/dpc.0904a11

Source DB:  PubMed          Journal:  Dermatol Pract Concept        ISSN： 2160-9381


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Authors:  C Paul; J Cather; M Gooderham; Y Poulin; U Mrowietz; C Ferrandiz; J Crowley; C Hu; R M Stevens; K Shah; R M Day; G Girolomoni; A B Gottlieb
Journal:  Br J Dermatol       Date:  2015-11-07       Impact factor: 9.302

2.  Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

Authors:  S S Pullamsetti; G A Banat; A Schmall; M Szibor; D Pomagruk; J Hänze; E Kolosionek; J Wilhelm; T Braun; F Grimminger; W Seeger; R T Schermuly; R Savai
Journal:  Oncogene       Date:  2012-04-23       Impact factor: 9.867
  2 in total
  4 in total

1.  Is Apremilast a Safe Option in Patients with History of Melanoma? A Case Series and a Review of the Literature.

Authors:  Alessio Gambardella; Gaetano Licata; Alina De Rosa; Giulia Calabrese; Roberto Alfano; Giuseppe Argenziano
Journal:  J Clin Aesthet Dermatol       Date:  2022-02

2.  Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.

Authors:  Maria Anna Siciliano; Stefano Dastoli; Maria d'Apolito; Nicoletta Staropoli; Pierfrancesco Tassone; Pierosandro Tagliaferri; Vito Barbieri
Journal:  Front Oncol       Date:  2020-10-14       Impact factor: 6.244

Review 3.  Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management.

Authors:  Zoe Apalla; Bernardo Rapoport; Vincent Sibaud
Journal:  Int J Womens Dermatol       Date:  2021-10-23

4.  Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2).

Authors:  J L W Lambert; S Segaert; P D Ghislain; T Hillary; A Nikkels; F Willaert; J Lambert; R Speeckaert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-08-13       Impact factor: 6.166
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.